Abstract

Central nervous system (CNS) toxicity is common at diagnosis and during treatment of pediatric acute lymphoblastic leukemia (ALL). We studied CNS toxicity in 1 464 children aged 1.0-17.9 years, diagnosed with ALL and treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol. Genome-wide association studies (GWAS), and a candidate single-nucleotide polymorphism (SNP; n=19) study were performed in 1 166 patients. Findings were validated in an Australian independent cohort of children with ALL (n=797) where two phenotypes were evaluated: diverse CNS toxicities (n=103) and methotrexate-related CNS toxicity (n=48). In total, 135/1 464 (9.2%) patients experienced CNS toxicity with cumulative incidence of 8.7% (95% CI: 7.31-10.20) at 12 months from diagnosis. Patients aged =10 years had higher risk of CNS toxicity than younger patients (16.3% vs 7.4%; p.

Authors	Anastasopoulou, Stavroula; Nielsen, Rikke Linnemann; Als-Nielsen, Bodil; Banerjee, Joanna; Eriksson, Mats A; Helenius, Marianne; Heyman, Mats M; Johannsdottir, Inga Maria; Jonsson, Olafur Gisli; MacGregor, Stuart; Mateos, Marion K; Mayoh, Chelsea; Mikkel, Sirje; Myrberg, Ida Hed; Niinimäki, Riitta; Schmiegelow, Kjeld; Taskinen, Mervi; Vaitkeviciene, Goda; Warnqvist, Anna; Wolthers, Benjamin; Harila-Saari, Arja; Ranta, Susanna
Journal	HAEMATOLOGICA
Pages
Volume
Date	1/01/2022
Grant ID
Funding Body
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.3324/haematol.2021.280016